Skip to main content

Table 4 Change in patient Ki67 and vimentin CTC profile with treatment. Chi-squared test to analyse CTC frequencies in treatment groups. Samples from the second column were taken at cycles 2–3 following initiation of treatment

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

 

Baseline sample before treatment (%)

First sample after treatment start (%)

 

Number of patients with Ki67 + ve CTC (%)

23/51 (45.1)

15/39 (38.5)

p = 0.528

Number of patients with ≥5 Ki67 + ve CTC (%)

12/51 (23.5)

6/39 (15.4)

p = 0.336

Number of patients with Vim + ve CTC (%)

30/93 (32.3)

19/49 (38.8)

p = 0.437

Number of patients with ≥5 Vim + ve CTC (%)

10/93 (10.8)

7/49 (14.3)

p = 0.558